多种β-内酰胺类抗菌药物对耐氧亚氨基头孢菌素的大肠埃希菌和克雷伯菌属临床分离株的体外活性。
In vitro activities of various beta-lactam antimicrobial agents against clinical isolates of Escherichia coli and Klebsiella spp. resistant to oxyimino cephalosporins.
作者信息
Jett B D, Ritchie D J, Reichley R, Bailey T C, Sahm D F
机构信息
Division of Laboratory Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
出版信息
Antimicrob Agents Chemother. 1995 May;39(5):1187-90. doi: 10.1128/AAC.39.5.1187.
Abstract
Broth microdilution testing was used to study the activity of several beta-lactam antimicrobial agents, including piperacillin-tazobactam and cefepime, against 108 clinically derived Escherichia coli and Klebsiella sp. strains resistant to oxyimino cephalosporins (i.e., putative extended-spectrum beta-lactamase producers). On the basis of the percentage of susceptible strains, imipenem (100%), cefotetan (> or = 92%), and piperacillin-tazobactam (> or = 86%) were the most active agents. Cefepime activity (52 to 64% susceptible) was comparable to that of cefotaxime (40 to 63% susceptible) and aztreonam (20 to 63% susceptible). Among all beta-lactams tested, imipenem and cefotetan demonstrated the highest and most consistent level of activity and were the least affected by challenges with increased sizes of inocula of these resistant organisms.
摘要
采用肉汤微量稀释试验研究了几种β-内酰胺类抗菌药物，包括哌拉西林-他唑巴坦和头孢吡肟，对108株临床分离的对氧亚氨基头孢菌素耐药的大肠埃希菌和克雷伯菌属菌株（即假定的超广谱β-内酰胺酶产生菌）的活性。根据敏感菌株的百分比，亚胺培南（100%）、头孢替坦（≥92%）和哌拉西林-他唑巴坦（≥86%）是活性最强的药物。头孢吡肟的活性（52%至64%敏感）与头孢噻肟（40%至63%敏感）和氨曲南（20%至63%敏感）相当。在所有测试的β-内酰胺类药物中，亚胺培南和头孢替坦表现出最高且最一致的活性水平，并且受这些耐药菌接种量增加的影响最小。
相似文献
1
In vitro activities of various beta-lactam antimicrobial agents against clinical isolates of Escherichia coli and Klebsiella spp. resistant to oxyimino cephalosporins.多种β-内酰胺类抗菌药物对耐氧亚氨基头孢菌素的大肠埃希菌和克雷伯菌属临床分离株的体外活性。
Antimicrob Agents Chemother. 1995 May;39(5):1187-90. doi: 10.1128/AAC.39.5.1187.
2
Can results obtained with commercially available MicroScan microdilution panels serve as an indicator of beta-lactamase production among escherichia coli and Klebsiella isolates with hidden resistance to expanded-spectrum cephalosporins and aztreonam?使用市售的MicroScan微量稀释板获得的结果能否作为大肠埃希菌和克雷伯菌分离株中β-内酰胺酶产生的指标，这些分离株对广谱头孢菌素和氨曲南存在隐匿性耐药？
J Clin Microbiol. 1998 Sep;36(9):2575-9. doi: 10.1128/JCM.36.9.2575-2579.1998.
3
Clinical and microbiologic analysis of a hospital's extended-spectrum beta-lactamase-producing isolates over a 2-year period.某医院两年期间产超广谱β-内酰胺酶菌株的临床与微生物学分析
Pharmacotherapy. 2003 Oct;23(10):1232-7. doi: 10.1592/phco.23.12.1232.32706.
4
5
Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype.针对具有超广谱β-内酰胺酶（ESBL）表型的全球大肠杆菌和克雷伯菌属菌株集合，头孢吡肟与哌拉西林/他唑巴坦的比较活性。
Diagn Microbiol Infect Dis. 2007 Mar;57(3):341-4. doi: 10.1016/j.diagmicrobio.2006.08.016. Epub 2006 Dec 1.
6
Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group.对六种广谱β-内酰胺抗菌药物针对来自日本22个医疗中心的2000多株临床分离菌的体外活性进行评估。日本抗菌药物耐药性研究组。
Diagn Microbiol Infect Dis. 1999 Jun;34(2):123-34. doi: 10.1016/s0732-8893(99)00019-x.
7
8
Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Cefepime Study Group.八种广谱β-内酰胺类药物的抗菌活性及谱研究：1997年在美国102个医疗中心进行的一项监测试验。头孢吡肟研究组。
Diagn Microbiol Infect Dis. 1998 Mar;30(3):215-28. doi: 10.1016/s0732-8893(97)00234-4.
9
Beta-lactam susceptibilities and prevalence of ESBL-producing isolates among more than 5000 European Enterobacteriaceae isolates.5000多株欧洲肠杆菌科细菌分离株的β-内酰胺敏感性及产超广谱β-内酰胺酶（ESBL）分离株的流行情况
Int J Antimicrob Agents. 2004 Dec;24(6):585-91. doi: 10.1016/j.ijantimicag.2004.08.008.
10
Update of incidence and antimicrobial susceptibility trends of Escherichia coli and Klebsiella pneumoniae isolates from Chinese intra-abdominal infection patients.中国腹腔感染患者大肠埃希菌和肺炎克雷伯菌分离株的发病率及抗菌药物敏感性趋势更新
BMC Infect Dis. 2017 Dec 18;17(1):776. doi: 10.1186/s12879-017-2873-z.
引用本文的文献
1
Changing Trend in the Antibiotic Resistance Pattern of Klebsiella Pneumonia Isolated From Endotracheal Aspirate Samples of ICU Patients of a Tertiary Care Hospital in North India.印度北部一家三级护理医院重症监护病房患者气管内吸出物样本中分离出的肺炎克雷伯菌抗生素耐药模式的变化趋势
Cureus. 2023 Mar 17;15(3):e36317. doi: 10.7759/cureus.36317. eCollection 2023 Mar.
2
Intense intestinal carriage and subsequent acquisition of multidrug-resistant enterobacteria in neonatal intensive care unit in Morocco.摩洛哥新生儿重症监护病房中肠内携带和随后获得的多重耐药肠杆菌。
PLoS One. 2021 Jun 30;16(6):e0251810. doi: 10.1371/journal.pone.0251810. eCollection 2021.
3
The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections.非碳青霉烯类β-内酰胺类药物在治疗产超广谱β-内酰胺酶感染中的应用
Clin Infect Dis. 2017 Apr 1;64(7):972-980. doi: 10.1093/cid/cix034.
4
Antibiotic Susceptibility Pattern of ESβL Producing Klebsiella pneumoniae Isolated from Urine Samples of Pregnant Women in Karnataka.从卡纳塔克邦孕妇尿液样本中分离出的产超广谱β-内酰胺酶肺炎克雷伯菌的抗生素敏感性模式
J Clin Diagn Res. 2014 Oct;8(10):DC08-11. doi: 10.7860/JCDR/2014/9594.5048. Epub 2014 Oct 20.
5
Extended-spectrum β-lactamases in Gram Negative Bacteria.革兰氏阴性菌中的超广谱β-内酰胺酶
J Glob Infect Dis. 2010 Sep;2(3):263-74. doi: 10.4103/0974-777X.68531.
6
Extended-spectrum beta-lactamases: a clinical update.超广谱β-内酰胺酶：临床最新进展
Clin Microbiol Rev. 2005 Oct;18(4):657-86. doi: 10.1128/CMR.18.4.657-686.2005.
7
Extended spectrum beta-lactamases in Eschericia coli isolated from community-acquired urinary tract infections in the Gaza Strip, Palestine.从巴勒斯坦加沙地带社区获得性尿路感染分离出的大肠埃希菌中的超广谱β-内酰胺酶
Ann Saudi Med. 2004 Jan-Feb;24(1):55-7. doi: 10.5144/0256-4947.2004.55.
8
Effects of inoculum and beta-lactamase activity in AmpC- and extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology.采用美国国家临床实验室标准委员会（NCCLS）的超广谱β-内酰胺酶（ESBL）检测方法，对产AmpC酶和ESBL的大肠埃希菌及肺炎克雷伯菌临床分离株，检测接种量和β-内酰胺酶活性的影响。
J Clin Microbiol. 2004 Jan;42(1):269-75. doi: 10.1128/JCM.42.1.269-275.2004.
9
In vitro and in vivo activities of AM-112, a novel oxapenem.新型氧青霉烯类药物AM - 112的体外和体内活性
Antimicrob Agents Chemother. 2003 May;47(5):1652-7. doi: 10.1128/AAC.47.5.1652-1657.2003.
10
Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.头孢吡肟、哌拉西林-他唑巴坦与产超广谱β-内酰胺酶肠杆菌科细菌检测中的接种物效应
Antimicrob Agents Chemother. 2001 Dec;45(12):3548-54. doi: 10.1128/AAC.45.12.3548-3554.2001.
本文引用的文献
1
In vitro activity and beta-lactamase stability of FK-037, a parenteral cephalosporin.注射用头孢菌素FK-037的体外活性及β-内酰胺酶稳定性
Antimicrob Agents Chemother. 1993 Mar;37(3):566-73. doi: 10.1128/AAC.37.3.566.
2
Molecular epidemiology of plasmid spread among extended broad-spectrum beta-lactamase-producing Klebsiella pneumoniae isolates in a pediatric hospital.一家儿童医院中产超广谱β-内酰胺酶肺炎克雷伯菌分离株间质粒传播的分子流行病学研究
J Clin Microbiol. 1993 Feb;31(2):179-84. doi: 10.1128/jcm.31.2.179-184.1993.
3
Cefepime: the next generation?头孢吡肟：新一代产品？
Clin Infect Dis. 1993 Sep;17(3):369-79.
4
Different ratios of the piperacillin-tazobactam combination for treatment of experimental meningitis due to Klebsiella pneumoniae producing the TEM-3 extended-spectrum beta-lactamase.不同比例的哌拉西林-他唑巴坦组合用于治疗由产TEM-3超广谱β-内酰胺酶的肺炎克雷伯菌引起的实验性脑膜炎。
Antimicrob Agents Chemother. 1994 Feb;38(2):195-9. doi: 10.1128/AAC.38.2.195.
5
Molecular characterization of an enterobacterial metallo beta-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance.在一株表现出亚胺培南耐药性的粘质沙雷氏菌临床分离株中发现的一种肠杆菌金属β-内酰胺酶的分子特征。
Antimicrob Agents Chemother. 1994 Jan;38(1):71-8. doi: 10.1128/AAC.38.1.71.
6
Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins.耐晚期头孢菌素的克雷伯菌感染的医院内暴发。
Ann Intern Med. 1993 Sep 1;119(5):353-8. doi: 10.7326/0003-4819-119-5-199309010-00001.
7
Multiply resistant Klebsiella pneumoniae strains from two Chicago hospitals: identification of the extended-spectrum TEM-12 and TEM-10 ceftazidime-hydrolyzing beta-lactamases in a single isolate.来自芝加哥两家医院的多重耐药肺炎克雷伯菌菌株：在单一分离株中鉴定出超广谱TEM-12和TEM-10头孢他啶水解β-内酰胺酶
Antimicrob Agents Chemother. 1994 Apr;38(4):761-6. doi: 10.1128/AAC.38.4.761.
8
In vivo efficacies of beta-lactam-beta-lactamase inhibitor combinations against a TEM-26-producing strain of Klebsiella pneumoniae.β-内酰胺-β-内酰胺酶抑制剂组合对产TEM-26型肺炎克雷伯菌菌株的体内疗效。
Antimicrob Agents Chemother. 1994 Nov;38(11):2663-4. doi: 10.1128/AAC.38.11.2663.
9
Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.哌拉西林/他唑巴坦：抗菌活性、药代动力学特性及治疗潜力综述
Drugs. 1994 Mar;47(3):506-35. doi: 10.2165/00003495-199447030-00008.
10
Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.头孢吡肟：抗菌活性、药代动力学特性及治疗用途综述
Drugs. 1994 Mar;47(3):471-505. doi: 10.2165/00003495-199447030-00007.
Zotero 插件